A message from WHO on sepsis
At the 70th World Health Assembly held on May 22nd-31st 2017 in Geneva, Switzerland, delegates agreed on a resolution to improve the prevention, diagnosis and treatment of sepsis, a global healthcare problem causing 5,300,000 deaths annually.
EUPHRATES RESULTS PRESENTATION – VICENZA COURSE 2017
At the 35th VICENZA COURSE on AKI and CRRT organized by Professor Claudio Ronco, held in Vicenza 13th–16th June, Professor Massimo Antonelli, President of the European Society of Intensive Care Medicine (ESICM) and member of the EUPHRATES trial steering committee, will present results from the EUPHRATES trial on Polymyxin B hemoperfusion in septic shock patients on 14th June at 17.30.
EUPHRATES trial – UPDATE
The fourth and final module of PMA application for FDA approval of Toraymyxin® has been submitted. A further data analysis of the EUPHRATES database identifies a population with significant mortality benefit when treated with Polymyxin B hemoperfusion therapy.
SURVIVING SEPSIS CAMPAIGN GUIDELINES 2016
The SSC guidelines are built on evidence-based medicine and are the most comprehensive guidelines available for the management of sepsis and septic shock.
Polymyxin B hemoperfusion therapy is included for the first time in the SSC guidelines, reflecting that evidence is accumulating for this therapy.
EUPHRATES RCT
EUPHRATES, an RCT performed in the USA and Canada on Polymyxin B hemoperfusion therapy (Toraymyxin®) has finished enrolment and the first results on the primary endpoints have recently been announced in a press release.
EUPHAS 2 WEB REGISTRY
EUPHAS 2 is a web-based registry for the collection of clinical data from patients undergoing Polymyxin B hemoperfusion therapy (Toraymyxin®). Data from 357 patients recorded during the first phase have been published recently in Annals of Intensive Care Medicine.